Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Debt (2018 - 2019)

10x Genomics (TXG) has disclosed Non-Current Debt for 2 consecutive years, with $19.8 million as the latest value for Q4 2019.

  • Quarterly Non-Current Debt fell 22.17% to $19.8 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Dec 2019, down 22.17% year-over-year, with the annual reading at $19.8 million for FY2019, 22.17% down from the prior year.
  • Non-Current Debt hit $19.8 million in Q4 2019 for 10x Genomics, down from $22.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $25.5 million in Q4 2018 to a low of $19.8 million in Q4 2019.